Corporate Vision
PISHON Biomedical Co., Ltd. is a company with the world's most advanced 3D cell culture scaffold research and development, production of patented technology and provided precision in-vitro medical one-stop service solutions, focused on precision medical science and technological company. Considering of the developmental view, included the current global and China's medical market development and technical resources, PISHON will focus on Taiwan as a foundation in the future, and go forward in China and prospect for the world.
 
 
2011  Completed the transfer of exclusive patented technology and established a production line and cell culture laboratory
 
2012  Launched 3D cell culture scaffold - CelluSponge
 
2013  Improved the surface of Cellusponge and supplied customized services
 
2014  Developed Bio-degradable plant-derived 3D cell culture scaffold
 
2015  Examined hepatic toxicity test in vitro, established primary cell culture, cancer cell lines and tumor 3D model and drug screening test
 
2016  Established drug screening platform in vitro for colorectal cancer, liver cancer and hepatitis B drug test model and signed a developmental plan with the hospitals
 
2017  Developed Patient Derived Organoid - Cancer Chemotherapy Sensitivity Test Services, Drug Screening service and Toxicological Test Contract Research Organization (CRO) Service and Circulating tumor cell Test (CTC) Service.
 

Main products/ Service item

Cancer screening medication guidance and monitoring one-stop service

PISHON Biomedical Co., Ltd. has advanced 3D cell culture system, promoting revolutionary changes in the field of cell culture in vitro. In recent years, this technology is widely used in the areas of pre-clinical drug screening, drug development and the establishment of tumor model, ect. Since 2016, PISHON has been actively involved in the development of the OncoTreat® platform, established patient-derived tumor organoid culture, drug sensitivity test of chemotherapeutic drugs, and provided clinical medication reference data. Compared with PDX (Animal Drug Sensitive Platform), this platform will shorten the testing cycle from an average of 5 months to 14-21 working days, meanwhile, high-throughput test will save exam costs and reduce the burden of the patient's financial and mind condition.

 
In 2016, the introduction of the PrimoCatcher® platform, it had an advantage that combined with positive and negative selections, provided highly accurate quantitative counting of circulating tumor cells for early screening, surgical evaluation and an effect of long-term track. The platform technology, clinical data is positively correlated with the post-operative development of patients and is published in international journals by Chang Gung Memorial Hospital. In combination with the OncoTreat® and PrimoCatcher® platforms, our established laboratory introduces for the cancer screening guidance and monitors a one-stop service, our customers include sub-healthy groups and early detection of pre-treatment, assessment of efficacy in treatment and post-treatment healing after the judge and regular track.
 
 
Drug screening and toxicological test - CRO service
 
New 3D drug screening platform technology in vitro can provide small molecule drug screening and toxicological tests.
 
TOP